In this section of the General Tradeshow News Site, you'll find event-related news releases from PR Newswire. The releases are listed in chronological order and are archived by month and year.
-Phase 1 Clinical Data Featured in Press Program and Oral Presentation Demonstrate 76 Percent Objective Response Rate, Including a 41 Percent Complete Remission Rate, in Newly Diagnosed AML Patients Treated with 33A Combination Therapy-
Cumulative Rates of Complete Response or Better Increased Over Time in Patients Treated With Kyprolis in Combination With Lenalidomide and Dexamethasone (KRd)